Health Catalyst Inc Stock (US42226A1079): Quarterly earnings put the data analytics specialist back in focus

Health Catalyst shares are trading quietly after the latest quarterly earnings update, as investors weigh slowing revenue, a narrower loss and management’s guidance against the company’s valuation on Nasdaq.

Responsible: ad hoc news Earnings Desk. Reviewed prior to publication on June 16, 2026 at 8:57 PM ET. Details in the imprint.

Health Catalyst Inc remains in focus for U.S. investors following its most recent quarterly earnings release, which showed modest revenue growth and a narrower net loss as the company continues to push toward profitability in its data and analytics offerings for healthcare providers. The stock trades on the Nasdaq under the ticker HCAT and gives U.S. investors exposure to healthcare analytics and value-based care technology. After the earnings report, the shares have traded without extreme swings, suggesting the market is still digesting the updated guidance and the company’s path toward breakeven.

Quarterly earnings: modest growth and a narrower loss

Health Catalyst reported first-quarter 2026 revenue in the low- to mid-double-digit percentage range above the prior-year period, driven mainly by growth in its technology subscription contracts with health systems and other healthcare organizations. The company’s core business centers on data platforms and analytics tools that aim to help providers improve clinical outcomes and financial performance, and subscription revenue continues to make up the majority of total sales. Management highlighted new and expanded customer wins in the quarter, indicating that health systems remain willing to invest in analytics capabilities despite broader cost pressures in the sector.

On the bottom line, Health Catalyst still reported a net loss, but the loss narrowed compared with the same quarter a year earlier as operating expenses grew more slowly than revenue. The company has been working to control sales and marketing costs and to streamline general and administrative spending, which contributed to better adjusted EBITDA results on a year-over-year basis. While the company has yet to achieve consistent profitability under U.S. GAAP, the direction of adjusted margins is important for investors who follow loss-making growth stories in the healthcare technology space.

Cash and equivalents remain a key metric for a company that is not yet consistently profitable, and Health Catalyst ended the quarter with a cash position that management characterized as sufficient to fund operations for the foreseeable future. The company has historically used a mix of equity and, to a lesser extent, debt financing, but it is currently emphasizing internal efficiency gains to reduce its cash burn. For U.S. retail investors, this balance between growth spending and cash preservation is central to assessing the risk profile of the stock.

Guidance for the full year 2026 indicates that management expects revenue growth to continue at a similar or slightly slower pace than in the latest quarter, reflecting both the macroeconomic environment in healthcare and the company’s own maturation. Health Catalyst also projects further improvement in adjusted EBITDA, aiming to move closer to breakeven as it scales its software platform and services while holding down operating cost growth. The guidance does not assume a sharp acceleration in demand but instead reflects incremental expansion within its existing customer base and selective new wins.

Analyst commentary around the earnings release has generally focused on the trade-off between slowing top-line growth and improving profitability metrics. Some research notes point out that the company’s valuation multiples are now more in line with other small- and mid-cap healthcare IT names, which may make the shares more sensitive to any upside or downside surprises relative to guidance. For investors following the broader digital health and analytics space, Health Catalyst’s quarterly update offers another data point on how hospital and provider IT budgets are evolving in a post-pandemic environment.

Trading in HCAT on Nasdaq following the earnings release has not shown extreme volatility compared with some earlier periods in the stock’s history, suggesting that the results were largely within the range of market expectations. Average daily trading volume remains moderate for a mid-cap healthcare technology stock, providing reasonable liquidity for U.S. retail investors but not the depth seen in larger S&P 500 names. Against this backdrop, the focus now shifts to execution over the remainder of the year as the company tries to align its growth investments with its path to profitability.

In summary, the latest quarterly earnings from Health Catalyst underscore a familiar theme in healthcare technology: measured revenue growth paired with steady progress toward narrower losses and improved operating efficiency. Investors watching the stock will likely pay close attention to future updates on contract wins, customer retention and margin trends to gauge whether the company can sustain its current trajectory without resorting to significant additional capital raises.

Health Catalyst at a glance

• Name: Health Catalyst Inc
• Industry: Healthcare technology and analytics
• Headquarters: Salt Lake City, Utah, United States
• Core markets: U.S. hospitals, health systems and other healthcare organizations
• Revenue drivers: Data platform subscriptions, analytics applications and related professional services
• Listing: Nasdaq, ticker HCAT
• Trading currency: U.S. dollars (USD)

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.